Effect of rosuvastatin and atorvastatin therapy on pregnancy-associated plasma protein-A in patients with coronary heart disease
Abstract：Objective To observe the effect of rosuvastatin and atorvastatin therapy on pregnancy-associated plasma protein-A(PAPP-A) in the patients with coronary heart disease(CHD). Meth-otis 117 patients with CHD verified by invasive coronary angiography were selected. Of them,46 had acute coronary syndrome(ACS,including non-ST-elevation myocardial infarction and unstable angina) and 71 had stable angina, They were randomly assigned to rosuvastatin(60 patients) and atorvastatin(57 patients) groups. PAPP-A, hs-CRP and lipids were measured before and after 1 and 6 months therapy. Results PAPP-A and hs-CRP were significantly increased in 46 patients with ACS compared with 71 patients with stable CHD (P<0.05). After 1 and 6 months therapy with rosuvastatin the level of PAPP-A was significantly decreased compared with baseline. Al-though the level of PAPP-A in atorvastatin group did not show difference at 1 month,it was sig-nificantly decreased at 6 months. Although the level of hs-CRP in both rosuvastatin and atorvasta-tin groups did not show difference at 1 month compared with baseline, it was significantly de-creased at 6 months (P < 0.05). There was no significant correlation between PAPP-A and hs-CRP. Conclusion Levels of PAPP-A and hs-CRP were significantly increased in patients with ACS compared with stable CAD, whereas they were significantly decreased in patients treated with rosuvastatin and atorvastatin.
Keywords：coronary diseasepregnancy-associated plasma protein-AC-reactive proteinantil-ipemic agents
Publication Date：2009-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 584-587 )